COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01070719
Recruitment Status : Completed
First Posted : February 18, 2010
Last Update Posted : March 1, 2012
Information provided by (Responsible Party):
John F. Foley, MD, Rocky Mountain MS Research Group, LLC

Brief Summary:
This is an open-label study of patients with relapsing forms of Multiple Sclerosis designed to assess the biochemical, immunological and pharmacokinetic profiles of a large, actively infusing natalizumab patient population. A duration effect for progressive multifocal leukoencephalopathy (PML) risk associated with natalizumab therapy appears to exist. There is minimal data available to understand this effect at the biochemical and cellular level. The purpose of this study is to gather preliminary data on several parameters to guide in more focused research on the duration effect.

Condition or disease
Multiple Sclerosis Relapse

Layout table for study information
Study Type : Observational
Actual Enrollment : 270 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort
Study Start Date : February 2010
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Natalizumab

Relapsing form of MS treated with natalizumab
Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.

Biospecimen Retention:   Samples Without DNA
Serum will be collected, and spun for specific tests. The back-up specimens (plasma)will be held in case of a laboratory error.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with relapsing forms of MS currently being treated with natalizumab.

Inclusion Criteria:

  1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  2. Aged 18 to 75 years old, inclusive, at the time of informed consent.
  3. Must be a patient with a relapsing form of Multiple Sclerosis enrolled in the TOUCH Prescribing Program who is not expected to discontinue Tysabri® therapy prior to completion of the requirements of this study.
  4. Must have been treated with monthly IV infusions of Tysabri® 300 mg for at least 1 month.
  5. Must have a magnetic resonance imaging (MRI) brain scan, performed prior to the initiation of treatment with Tysabri®, on file.
  6. Must weigh between 42 and 126 kg, inclusive.
  7. Fifteen patients who are 1 month to-12 months of natalizumab therapy, fifteen patients who are 24 months and over of natalizumab therapy will be asked to participate in the TNF alpha subset.

Exclusion Criteria:

Medical History:

  1. History of, or abnormal laboratory results indicative of, any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
  2. If subject answers 'Yes" to any question on the PML questionnaire that is not resolved prior to infusion as per standard operating procedure for natalizumab infusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01070719

Layout table for location information
United States, Utah
Rocky Mountain Multiple Sclerosis Clinic
Salt Lake City, Utah, United States, 84103
Sponsors and Collaborators
John F. Foley, MD
Layout table for investigator information
Principal Investigator: John F Foley, MD Rocky Mountain MS Research Group, LLC
Layout table for additonal information
Responsible Party: John F. Foley, MD, Sponsor-Investigator, Rocky Mountain MS Research Group, LLC Identifier: NCT01070719    
Other Study ID Numbers: 001-001-TY
First Posted: February 18, 2010    Key Record Dates
Last Update Posted: March 1, 2012
Last Verified: February 2012
Keywords provided by John F. Foley, MD, Rocky Mountain MS Research Group, LLC:
Multiple Sclerosis, relapsing forms
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases